A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

An Open-Label Clinical Study to Evaluate the Effects of Multiple Oral Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-4646 in Healthy Participants

Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB).

Researchers want to learn about MK-4646 when taken at the same time as Rifabutin.

They want to:

Measure a person's blood to find out if the amount of MK-4646 in the blood is the same when MK-4646 is taken alone or with Rifabutin Learn about the safety of MK-4646 when taken alone or with Rifabutin and if people tolerate it

The main inclusion criteria include but are not limited to:

• Is in good health
• Has a body-mass index (BMI) between 18 and 32 kg/m2

The main exclusion criteria include but are not limited to:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of cancer (malignancy)